FluCide will initially be investigated against the 1930 H1N1 strain.

NanoViricides  signed a preclinical study agreement for the evaluation of FluCide™, its universal anti-influenza drug candidate. Thevac, a spin-off of the Louisiana State University, will conduct the study.

Initially, the research will evaluate effectiveness of nanoviricide™ drug candidates against a virulent H1N1 strain that caused a severe outbreak in 1930. This well-characterized virus is expected to be a good surrogate for the current swine flu. The study will then be expanded to include other influenza subtypes that are feared to be on the horizon, such as H3N2.

FluCide is currently in IND-enabling studies in bird flu. NanoViricides believes that it is possible to design a single drug capable of attacking most influenza viruses, because they all use the same cell-surface receptor, sialic acid.

Past News from NanoViricides
Nanoviricides and Walter Reed Team Up to Fight Dengue Fever (Apr. 9, 2007)

Previous articleBIO Supersession Intellectual Property at the Crossroads
Next articleMetabasis Makes Third Workforce Cut and Is Left with Seven Employees